Share Price and Basic Stock Data
Last Updated: December 18, 2025, 10:54 pm
| PEG Ratio | 1.51 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
ARCL Organics Ltd operates within the chemicals sector, focusing primarily on organic compounds. As of the latest data, the company’s stock price stands at ₹351, with a market capitalization of ₹281 Cr. Over the past few years, ARCL has demonstrated a commendable growth trajectory in its revenue. For instance, sales rose from ₹141 Cr in March 2022 to ₹165 Cr in March 2023, and are projected to reach ₹191 Cr by March 2024. The trailing twelve months (TTM) figure recently reported is ₹258 Cr, indicating a strong upward trend. However, it’s worth noting that while quarterly sales fluctuate—recording ₹46.44 Cr in March 2023 and ₹41.58 Cr in June 2023—the overall growth narrative remains robust, suggesting resilience against market volatility. The company’s ability to adapt and innovate within the organic chemicals space is crucial for sustaining this growth momentum.
Profitability and Efficiency Metrics
ARCL’s profitability metrics present a mixed picture, with operating profit margins (OPM) hovering around 9.5% currently. This is a decline from the highs of 14% observed in March 2021, reflecting increased competition and potential cost pressures. The reported net profit for the recent quarter ending September 2023 was ₹0.91 Cr, which, while lower compared to some previous quarters, still shows a capacity to generate positive earnings. The return on equity (ROE) stands at 16.8%, above the sector average, suggesting effective utilization of shareholder funds. Additionally, the interest coverage ratio (ICR) is a healthy 6.23x, indicating that ARCL can comfortably meet its interest obligations. However, the declining net profit in some quarters raises concerns about the sustainability of margins and efficiency moving forward.
Balance Sheet Strength and Financial Ratios
Examining ARCL’s balance sheet reveals a reasonable financial footing with total borrowings at ₹42 Cr, which is manageable given the reserves of ₹78 Cr. This results in a debt-to-equity ratio of 0.43, showing that the company’s leverage is within a comfortable range. Moreover, the current ratio of 1.48 indicates that ARCL possesses sufficient short-term assets to cover its liabilities. The price-to-book value ratio of 2.37x suggests that investors are willing to pay a premium for the stock, reflecting positive sentiment towards its growth potential. However, the rising expenses—recorded at ₹171 Cr for March 2024—could pose challenges if not managed effectively. The company’s ability to balance growth with cost control will be pivotal in maintaining its financial health.
Shareholding Pattern and Investor Confidence
ARCL’s shareholding structure reveals a strong promoter backing, with promoters holding 69.22% of the equity. This substantial stake indicates confidence from the founders in the company’s direction. However, institutional investor interest appears limited, with foreign institutional investors (FIIs) absent and domestic institutional investors (DIIs) holding a meager 0.75%. This could imply a lack of broader market confidence in the stock, potentially making it vulnerable to volatility. The public shareholding stands at 30.03%, with a growing number of shareholders, reaching 7,929 as of September 2025. This growth in retail participation may provide a buffer against sudden market movements, yet it also emphasizes the need for the company to enhance its visibility and attractiveness to institutional investors.
Outlook, Risks, and Final Insight
The outlook for ARCL Organics Ltd appears cautiously optimistic, yet several risks loom on the horizon. The company’s dependence on the organic chemicals market exposes it to fluctuations in raw material prices and regulatory changes that could impact profitability. Moreover, while the growth in sales is promising, the declining margins suggest that the company may face challenges in maintaining profitability amid rising competition. Investors should also consider the limited institutional interest as a potential red flag, which could affect stock liquidity and price stability. Ultimately, ARCL’s ability to innovate, manage costs, and attract institutional support will be critical for sustaining its growth trajectory. Retail investors should weigh these factors carefully, balancing the potential for growth against the inherent risks associated with the chemicals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 100.0 Cr. | 280 | 456/255 | 232 | 392 | 0.04 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,352 Cr. | 9,273 | 14,250/8,150 | 53.2 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 34.8 Cr. | 116 | 329/109 | 17.2 | 26.9 | 0.86 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 32.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 312 Cr. | 390 | 435/163 | 17.3 | 108 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,623.25 Cr | 1,524.36 | 65.05 | 334.84 | 0.41% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41.00 | 31.71 | 46.44 | 41.58 | 43.25 | 48.33 | 57.57 | 59.93 | 56.46 | 61.96 | 72.24 | 67.34 |
| Expenses | 36.27 | 30.36 | 40.04 | 38.47 | 39.51 | 41.00 | 52.20 | 54.12 | 51.33 | 58.14 | 63.25 | 60.94 |
| Operating Profit | 4.73 | 1.35 | 6.40 | 3.11 | 3.74 | 7.33 | 5.37 | 5.81 | 5.13 | 3.82 | 8.99 | 6.40 |
| OPM % | 11.54% | 4.26% | 13.78% | 7.48% | 8.65% | 15.17% | 9.33% | 9.69% | 9.09% | 6.17% | 12.44% | 9.50% |
| Other Income | 0.58 | 0.01 | 2.25 | 0.43 | 0.64 | 0.81 | 0.82 | 0.41 | 0.71 | 0.83 | 0.40 | 0.83 |
| Interest | 0.44 | 0.45 | 0.51 | 0.51 | 1.03 | 1.85 | 0.76 | 1.25 | 1.23 | 1.14 | 1.24 | 1.17 |
| Depreciation | 1.00 | 0.64 | 1.30 | 1.33 | 1.29 | 1.17 | 0.50 | 1.37 | 1.13 | 1.29 | 1.42 | 1.39 |
| Profit before tax | 3.87 | 0.27 | 6.84 | 1.70 | 2.06 | 5.12 | 4.93 | 3.60 | 3.48 | 2.22 | 6.73 | 4.67 |
| Tax % | 28.94% | 29.63% | 73.39% | 16.47% | 55.83% | 30.86% | 2.03% | 27.22% | 42.53% | 24.77% | 19.02% | 18.42% |
| Net Profit | 2.76 | 0.19 | 1.81 | 1.42 | 0.91 | 3.53 | 4.83 | 2.62 | 2.01 | 1.67 | 5.46 | 3.81 |
| EPS in Rs | 3.45 | 0.24 | 2.26 | 1.78 | 1.14 | 4.41 | 6.04 | 3.28 | 2.51 | 2.09 | 6.82 | 4.76 |
Last Updated: August 19, 2025, 11:30 pm
Below is a detailed analysis of the quarterly data for ARCL Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 67.34 Cr.. The value appears to be declining and may need further review. It has decreased from 72.24 Cr. (Mar 2025) to 67.34 Cr., marking a decrease of 4.90 Cr..
- For Expenses, as of Jun 2025, the value is 60.94 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 63.25 Cr. (Mar 2025) to 60.94 Cr., marking a decrease of 2.31 Cr..
- For Operating Profit, as of Jun 2025, the value is 6.40 Cr.. The value appears to be declining and may need further review. It has decreased from 8.99 Cr. (Mar 2025) to 6.40 Cr., marking a decrease of 2.59 Cr..
- For OPM %, as of Jun 2025, the value is 9.50%. The value appears to be declining and may need further review. It has decreased from 12.44% (Mar 2025) to 9.50%, marking a decrease of 2.94%.
- For Other Income, as of Jun 2025, the value is 0.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.40 Cr. (Mar 2025) to 0.83 Cr., marking an increase of 0.43 Cr..
- For Interest, as of Jun 2025, the value is 1.17 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.24 Cr. (Mar 2025) to 1.17 Cr., marking a decrease of 0.07 Cr..
- For Depreciation, as of Jun 2025, the value is 1.39 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.42 Cr. (Mar 2025) to 1.39 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.67 Cr.. The value appears to be declining and may need further review. It has decreased from 6.73 Cr. (Mar 2025) to 4.67 Cr., marking a decrease of 2.06 Cr..
- For Tax %, as of Jun 2025, the value is 18.42%. The value appears to be improving (decreasing) as expected. It has decreased from 19.02% (Mar 2025) to 18.42%, marking a decrease of 0.60%.
- For Net Profit, as of Jun 2025, the value is 3.81 Cr.. The value appears to be declining and may need further review. It has decreased from 5.46 Cr. (Mar 2025) to 3.81 Cr., marking a decrease of 1.65 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.76. The value appears to be declining and may need further review. It has decreased from 6.82 (Mar 2025) to 4.76, marking a decrease of 2.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:12 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 49 | 71 | 71 | 87 | 141 | 165 | 191 | 251 | 288 |
| Expenses | 46 | 67 | 64 | 74 | 126 | 147 | 171 | 227 | 257 |
| Operating Profit | 2 | 4 | 7 | 12 | 15 | 18 | 20 | 24 | 31 |
| OPM % | 5% | 6% | 10% | 14% | 11% | 11% | 10% | 9% | 11% |
| Other Income | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 |
| Interest | 2 | 2 | 3 | 2 | 2 | 2 | 4 | 5 | 5 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 5 | 6 |
| Profit before tax | 1 | 2 | 3 | 10 | 15 | 17 | 14 | 16 | 24 |
| Tax % | 45% | 26% | 24% | 29% | 29% | 30% | 23% | 27% | |
| Net Profit | 1 | 1 | 3 | 7 | 10 | 12 | 11 | 12 | 18 |
| EPS in Rs | 0.70 | 1.40 | 3.21 | 9.14 | 13.10 | 14.72 | 13.38 | 14.69 | 22.52 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 200.00% | 133.33% | 42.86% | 20.00% | -8.33% | 9.09% |
| Change in YoY Net Profit Growth (%) | 0.00% | 200.00% | -66.67% | -90.48% | -22.86% | -28.33% | 17.42% |
ARCL Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 2:21 pm
Balance Sheet
Last Updated: December 10, 2025, 3:50 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 13 | 14 | 16 | 24 | 34 | 46 | 56 | 68 | 78 |
| Borrowings | 10 | 20 | 17 | 10 | 16 | 20 | 29 | 35 | 42 |
| Other Liabilities | 18 | 15 | 13 | 26 | 35 | 39 | 55 | 50 | 48 |
| Total Liabilities | 49 | 57 | 55 | 67 | 93 | 113 | 148 | 161 | 176 |
| Fixed Assets | 18 | 21 | 20 | 20 | 26 | 45 | 62 | 67 | 70 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other Assets | 30 | 35 | 33 | 47 | 66 | 66 | 85 | 93 | 105 |
| Total Assets | 49 | 57 | 55 | 67 | 93 | 113 | 148 | 161 | 176 |
Below is a detailed analysis of the balance sheet data for ARCL Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Reserves, as of Sep 2025, the value is 78.00 Cr.. The value appears strong and on an upward trend. It has increased from 68.00 Cr. (Mar 2025) to 78.00 Cr., marking an increase of 10.00 Cr..
- For Borrowings, as of Sep 2025, the value is 42.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 35.00 Cr. (Mar 2025) to 42.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 48.00 Cr.. The value appears to be improving (decreasing). It has decreased from 50.00 Cr. (Mar 2025) to 48.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 176.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 161.00 Cr. (Mar 2025) to 176.00 Cr., marking an increase of 15.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 70.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 105.00 Cr.. The value appears strong and on an upward trend. It has increased from 93.00 Cr. (Mar 2025) to 105.00 Cr., marking an increase of 12.00 Cr..
- For Total Assets, as of Sep 2025, the value is 176.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2025) to 176.00 Cr., marking an increase of 15.00 Cr..
Notably, the Reserves (78.00 Cr.) exceed the Borrowings (42.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -8.00 | -16.00 | -10.00 | 2.00 | -1.00 | -2.00 | -9.00 | -11.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 87 | 87 | 96 | 82 | 71 | 65 | 75 |
| Inventory Days | 59 | 35 | 45 | 40 | 43 | 38 | 58 | 28 |
| Days Payable | 102 | 51 | 43 | 89 | 88 | 83 | 110 | 75 |
| Cash Conversion Cycle | 55 | 71 | 89 | 48 | 37 | 25 | 13 | 28 |
| Working Capital Days | 56 | 84 | 32 | 49 | 46 | 31 | 25 | 28 |
| ROCE % | 9% | 15% | 30% | 33% | 28% | 21% | 20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 15.42 | 14.12 | 14.59 | 13.16 | 10.04 |
| Diluted EPS (Rs.) | 15.42 | 14.12 | 14.59 | 13.16 | 10.04 |
| Cash EPS (Rs.) | 21.93 | 19.49 | 17.93 | 14.95 | 11.90 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 96.81 | 81.88 | 67.81 | 53.18 | 40.21 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 96.81 | 81.88 | 67.81 | 53.18 | 40.21 |
| Revenue From Operations / Share (Rs.) | 313.24 | 238.40 | 206.32 | 176.58 | 108.34 |
| PBDIT / Share (Rs.) | 32.70 | 27.52 | 26.63 | 22.04 | 18.27 |
| PBIT / Share (Rs.) | 26.19 | 22.15 | 23.30 | 20.25 | 16.42 |
| PBT / Share (Rs.) | 20.94 | 18.31 | 20.87 | 18.56 | 14.03 |
| Net Profit / Share (Rs.) | 15.41 | 14.13 | 14.59 | 13.16 | 10.04 |
| NP After MI And SOA / Share (Rs.) | 15.41 | 14.13 | 14.59 | 13.16 | 10.04 |
| PBDIT Margin (%) | 10.43 | 11.54 | 12.90 | 12.48 | 16.86 |
| PBIT Margin (%) | 8.36 | 9.29 | 11.29 | 11.46 | 15.15 |
| PBT Margin (%) | 6.68 | 7.68 | 10.11 | 10.50 | 12.95 |
| Net Profit Margin (%) | 4.92 | 5.92 | 7.07 | 7.45 | 9.27 |
| NP After MI And SOA Margin (%) | 4.92 | 5.92 | 7.07 | 7.45 | 9.27 |
| Return on Networth / Equity (%) | 15.92 | 17.25 | 21.51 | 24.75 | 24.97 |
| Return on Capital Employeed (%) | 20.80 | 19.94 | 26.46 | 31.05 | 32.01 |
| Return On Assets (%) | 7.30 | 7.18 | 9.70 | 11.13 | 12.83 |
| Long Term Debt / Equity (X) | 0.20 | 0.27 | 0.19 | 0.08 | 0.06 |
| Total Debt / Equity (X) | 0.43 | 0.44 | 0.37 | 0.33 | 0.26 |
| Asset Turnover Ratio (%) | 1.54 | 1.37 | 1.54 | 0.00 | 1.48 |
| Current Ratio (X) | 1.48 | 1.37 | 1.47 | 1.59 | 1.94 |
| Quick Ratio (X) | 1.27 | 1.04 | 1.22 | 1.30 | 1.65 |
| Inventory Turnover Ratio (X) | 13.80 | 7.98 | 9.77 | 0.00 | 9.59 |
| Interest Coverage Ratio (X) | 6.23 | 7.17 | 10.99 | 13.03 | 7.66 |
| Interest Coverage Ratio (Post Tax) (X) | 3.94 | 4.68 | 7.02 | 8.78 | 5.21 |
| Enterprise Value (Cr.) | 198.81 | 48.46 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.79 | 0.25 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 7.60 | 2.20 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.73 | 0.18 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.37 | 0.52 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.73 | 0.18 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.06 | 0.32 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for ARCL Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 15.42. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 15.42, marking an increase of 1.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is 15.42. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 15.42, marking an increase of 1.30.
- For Cash EPS (Rs.), as of Mar 25, the value is 21.93. This value is within the healthy range. It has increased from 19.49 (Mar 24) to 21.93, marking an increase of 2.44.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.81. It has increased from 81.88 (Mar 24) to 96.81, marking an increase of 14.93.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.81. It has increased from 81.88 (Mar 24) to 96.81, marking an increase of 14.93.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 313.24. It has increased from 238.40 (Mar 24) to 313.24, marking an increase of 74.84.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 32.70. This value is within the healthy range. It has increased from 27.52 (Mar 24) to 32.70, marking an increase of 5.18.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from 22.15 (Mar 24) to 26.19, marking an increase of 4.04.
- For PBT / Share (Rs.), as of Mar 25, the value is 20.94. This value is within the healthy range. It has increased from 18.31 (Mar 24) to 20.94, marking an increase of 2.63.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 15.41. This value is within the healthy range. It has increased from 14.13 (Mar 24) to 15.41, marking an increase of 1.28.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 15.41. This value is within the healthy range. It has increased from 14.13 (Mar 24) to 15.41, marking an increase of 1.28.
- For PBDIT Margin (%), as of Mar 25, the value is 10.43. This value is within the healthy range. It has decreased from 11.54 (Mar 24) to 10.43, marking a decrease of 1.11.
- For PBIT Margin (%), as of Mar 25, the value is 8.36. This value is below the healthy minimum of 10. It has decreased from 9.29 (Mar 24) to 8.36, marking a decrease of 0.93.
- For PBT Margin (%), as of Mar 25, the value is 6.68. This value is below the healthy minimum of 10. It has decreased from 7.68 (Mar 24) to 6.68, marking a decrease of 1.00.
- For Net Profit Margin (%), as of Mar 25, the value is 4.92. This value is below the healthy minimum of 5. It has decreased from 5.92 (Mar 24) to 4.92, marking a decrease of 1.00.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.92. This value is below the healthy minimum of 8. It has decreased from 5.92 (Mar 24) to 4.92, marking a decrease of 1.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.92. This value is within the healthy range. It has decreased from 17.25 (Mar 24) to 15.92, marking a decrease of 1.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.80. This value is within the healthy range. It has increased from 19.94 (Mar 24) to 20.80, marking an increase of 0.86.
- For Return On Assets (%), as of Mar 25, the value is 7.30. This value is within the healthy range. It has increased from 7.18 (Mar 24) to 7.30, marking an increase of 0.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.27 (Mar 24) to 0.20, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.43. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.43, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.54. It has increased from 1.37 (Mar 24) to 1.54, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has increased from 1.37 (Mar 24) to 1.48, marking an increase of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 1.27. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.27, marking an increase of 0.23.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 13.80. This value exceeds the healthy maximum of 8. It has increased from 7.98 (Mar 24) to 13.80, marking an increase of 5.82.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.23. This value is within the healthy range. It has decreased from 7.17 (Mar 24) to 6.23, marking a decrease of 0.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.94. This value is within the healthy range. It has decreased from 4.68 (Mar 24) to 3.94, marking a decrease of 0.74.
- For Enterprise Value (Cr.), as of Mar 25, the value is 198.81. It has increased from 48.46 (Mar 24) to 198.81, marking an increase of 150.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 1. It has increased from 0.25 (Mar 24) to 0.79, marking an increase of 0.54.
- For EV / EBITDA (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 2.20 (Mar 24) to 7.60, marking an increase of 5.40.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.18 (Mar 24) to 0.73, marking an increase of 0.55.
- For Price / BV (X), as of Mar 25, the value is 2.37. This value is within the healthy range. It has increased from 0.52 (Mar 24) to 2.37, marking an increase of 1.85.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.18 (Mar 24) to 0.73, marking an increase of 0.55.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.32 (Mar 24) to 0.06, marking a decrease of 0.26.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ARCL Organics Ltd:
- Net Profit Margin: 4.92%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.8% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.92% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.94
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.27
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.3 (Industry average Stock P/E: 65.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.43
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.92%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | Rampur, P.S. Maheshtala, Budge Budge Trunk Road, Kolkata West Bengal 700141 | legal@arcl.in http://www.arclorganics.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suraj Ratan Mundhra | Chairman & Managing Director |
| Mr. Rajesh Mundhra | Executive Director |
| Mr. Brij Mohan Mohta | Ind. Non-Executive Director |
| Mrs. Stuti Pithisaria | Ind. Non-Executive Director |
| Mr. Prateek Chaudhary | Ind. Non-Executive Director |
| Mr. Mukesh Mundra | Executive Director |
FAQ
What is the intrinsic value of ARCL Organics Ltd?
ARCL Organics Ltd's intrinsic value (as of 19 December 2025) is 256.14 which is 34.32% lower the current market price of 390.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 312 Cr. market cap, FY2025-2026 high/low of 435/163, reserves of ₹78 Cr, and liabilities of 176 Cr.
What is the Market Cap of ARCL Organics Ltd?
The Market Cap of ARCL Organics Ltd is 312 Cr..
What is the current Stock Price of ARCL Organics Ltd as on 19 December 2025?
The current stock price of ARCL Organics Ltd as on 19 December 2025 is 390.
What is the High / Low of ARCL Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of ARCL Organics Ltd stocks is 435/163.
What is the Stock P/E of ARCL Organics Ltd?
The Stock P/E of ARCL Organics Ltd is 17.3.
What is the Book Value of ARCL Organics Ltd?
The Book Value of ARCL Organics Ltd is 108.
What is the Dividend Yield of ARCL Organics Ltd?
The Dividend Yield of ARCL Organics Ltd is 0.00 %.
What is the ROCE of ARCL Organics Ltd?
The ROCE of ARCL Organics Ltd is 20.4 %.
What is the ROE of ARCL Organics Ltd?
The ROE of ARCL Organics Ltd is 16.8 %.
What is the Face Value of ARCL Organics Ltd?
The Face Value of ARCL Organics Ltd is 10.0.